Navigation Links
Accera, Inc. Announces Results of Phase II Study in Alzheimer's,Disease at American Academy of Neurology Meeting

BROOMFIELD, Colo., May 01, 2007 /PRNewswire/ -- Accera Inc. is presenting topline data today from its Phase IIb study of its lead compound AC-1202 in Alzheimer's disease (AD) at the American Academy of Neurology (AAN) 59th Annual Meeting in Boston. Judged by the AAN to be in the top five percent of the program, the data will also be featured in the Scientific Highlights Plenary Session.

The randomized, double-blinded, placebo-controlled Phase IIb trial evaluated 152 subjects that had previously been diagnosed with mild to moderate AD. Consistent with the findings of Accera's Phase IIa study, subjects who did not have the ApoE4 genotype-a known genetic risk factor that occurs in half of all AD patients-responded particularly well to treatment, as reflected in statistically significant improvement in AD Assessment Scale- Cognitive (ADAS-Cog) scores.

Subjects underwent pharmacogenomic analysis for a variety of genetic markers and were evaluated through a battery of neuropsychometric tests at Day 0, 45, and 90. Compared to the placebo group, the ADAS-Cog scores of the AC- 1202-treated ApoE4(-) population improved 3.5 points in twelve weeks (p=0.01), and statistically significant improvement was seen in just 45 days.

Interestingly, ApoE4(-) subjects who also exhibited a genetic variation that affects glucose regulation showed a 5 point improvement in ADAS-Cog scores compared to placebo, providing further insight into the disease. "The profound effect we see in the population without the ApoE4 risk factor supports the findings of an earlier study linking efficacy to a certain pharmacogenomic profile," said Dr. Lauren Costantini, Accera's vice president of clinical development. "It also provides further evidence of the link between Alzheimer's disease and glucose metabolism."

Regardless of genotype, subjects treated with AC-1202 showed a trend toward improvement (p=.072), suggesting the com pound's disease modifying potential. Taken in addition to an existing AD treatment, AC-1202 was well tolerated, making it a promising co-therapeutic candidate for the chronic treatment of the disease.

Dr. Lauren Costantini is presenting the abstract, "Clinical Efficacy of AC-1202 in Mild to Moderate Alzheimer's Disease" at the Late Breaking Science session today at 3:45 p.m. EDT. The plenary session will be held at 5:15 p.m. EDT on Friday, May 4.

The trial was conducted at 25 centers across the United States, and all subjects were given the opportunity to participate in a six-month open-label extension upon completion of the three-month blinded study. The results of the open-label extension will be presented at the Alzheimer's Association's International Prevention Conference in early June.

About AC-1202

Brain imaging techniques performed on AD patients reveal a dramatically decreased uptake of glucose, the brain's preferred source of energy. AC-1202 is an orally available, liquid compound that is efficiently converted by the liver into ketone bodies, an alternative energy source that the brain can metabolize even when it cannot process glucose. Thus preserving the glucose- deprived brain cells, AC-1202 has disease modifying potential in AD and a number other neurodegenerative diseases characterized by neuronal metabolism. The potentially neuroprotective mechanism of this first-in-class compound is also being evaluated in age-associated memory impairment, Parkinson's disease, and canine cognitive dysfunction.

About Accera, Inc.

Based in Broomfield, CO, Accera, Inc. is a privately held biopharmaceutical company focused on developing novel drugs for neurodegenerative diseases. The company's lead candidate, AC-1202, is a first- in-class molecule currently in Phase II clinical trials for Alzheimer's disease and age-associated memory impairment. A key element of Accera's strategy is to develop AC-1202 and other small molecule com pounds in its pipeline with corporate partners for a range of memory and cognition disorders associated with neurological conditions and aging. www.accerapharma.com

    For information contact:

    Meghan Feeks

    Richard Lewis Communications, Inc.

    212-827-0020

    

mfeeks@rlcinc.com

CONTACT: Meghan Feeks of Richard Lewis Communications, Inc., for AcceraInc. +1-212-827-0020, or mfeeks@rlcinc.com

Web site: http://www.accerapharma.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
2. Accera, Inc. to Present Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
Breaking Medicine Technology:
(Date:4/29/2017)... ... April 29, 2017 , ... TransDark is a set ... one video to the next without having to set a single keyframe in ... to enhance your video production. , TransDark features dynamic transitions that momentarily splits the ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... An April 24th article on ... stunning 180 pounds with the help of a weight loss surgery. The woman, declaring “I ... skin that have been left following her dramatic weight loss. Dr. Feiz & Associates notes ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Beginning in 2017, ... their formulas. This begins with the popular ClearLungs Extra Strength formula. To ensure that ... the formula in the following ways:, , Removal of the ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
(Date:4/28/2017)... ... April 28, 2017 , ... From ... College of Urgent Care Medicine will host industry leaders for the annual spring ... help those in the industry adapt to the issues currently affecting urgent care ...
Breaking Medicine News(10 mins):